2024 Financial Guidance:
For the twelve months ending December 31, 2024, the Company now expects:
- Net sales of $562 million to $567 million, reflecting an increase of $2.5 million from the midpoint of previous guidance
- Adjusted EBITDA* of $104 million to $107 million
- Non-GAAP EPS* of $0.40 to $0.42, reflecting an increase of $0.02 from the midpoint of previous guidance
Recent Business Highlights
Bioventus continues to advance its strategic priorities with key achievements, including the following:
- Delivered four consecutive quarters of double-digit revenue growth in Pain Treatments and Surgical Solutions, which contributed to an 8.4% increase in Adjusted EBITDA*
- Reached an agreement to divest the Company's Advanced Rehabilitation Business for up to $45.0 million, which is anticipated to close near the end of 2024 or early 2025 and is expected to reduce debt and enable greater focus on execution within our remaining core businesses
Third Quarter 2024 Earnings Conference Call:
Management will host a conference call to discuss the Company’s financial results and provide a business update, with a question and answer session, at 8:30 a.m. Eastern Time on November 5, 2024. Those who would like to participate may dial 1-833-636-0497 (domestic and international) and refer to Bioventus Inc.
A live webcast of the call and any accompanying materials will also be provided on the investor relations section of the Company's website at https://ir.bioventus.com/.
The webcast will be archived on the Company’s website at https://ir.bioventus.com/ and available for replay until November 4, 2025.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.